LifeStance Health announces offering of 35 million shares by stockholders; company won't receive proceeds, plans to repurchase 6 million shares.
Quiver AI Summary
LifeStance Health Group, Inc. announced a stock offering in which certain stockholders plan to sell 35 million shares of the company’s common stock, with the proceeds going solely to the selling stockholders. LifeStance will not sell any shares or receive any proceeds from this offering. Additionally, the company has approved the concurrent purchase of 6 million shares from the underwriter, subject to the completion of the offering. J.P. Morgan is acting as the underwriter, and the offering is made under an automatic shelf registration statement filed with the SEC. Individuals interested in the offering should refer to the prospectus for detailed information. The press release also includes various forward-looking statements that discuss potential risks and uncertainties affecting the business.
Potential Positives
- The offering of 35,000,000 shares by certain stockholders indicates strong demand for LifeStance's stock, which could enhance the company's valuation in the market.
- The concurrent authorization for the repurchase of 6,000,000 shares demonstrates the company's commitment to returning value to its shareholders, which could boost investor confidence.
- The solid framework of regulated capital raises, as evidenced by the shelf registration statement, positions LifeStance for future financial flexibility and growth opportunities.
- LifeStance operates with a large workforce of over 8,300 professionals across 33 states, highlighting its significant operational scale in the mental health care sector, which is newsworthy in terms of its market position.
Potential Negatives
- The company is not raising any funds through this stock offering, which may signal a lack of liquidity or financial resilience.
- Large stock sell-off by current stockholders could indicate lack of confidence in the company's future prospects among existing investors.
- The need for a repurchase of shares suggests potential volatility or pressure on the stock price following the offering.
FAQ
What is the purpose of LifeStance's stock offering?
The stock offering aims to allow certain stockholders to sell 35,000,000 shares of LifeStance's common stock.
Who will receive the proceeds from this stock offering?
The Selling Stockholders will receive all proceeds from the offering, while LifeStance will not receive any.
Is LifeStance selling any shares in this offering?
No, LifeStance is not selling any shares nor will it receive any proceeds from the offering.
What additional transaction is LifeStance planning concurrently?
LifeStance has authorized the repurchase of 6,000,000 shares of its common stock from the underwriter upon completion of the offering.
Who is the underwriter for this stock offering?
J.P. Morgan is acting as the underwriter for LifeStance's stock offering.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LFST Insider Trading Activity
$LFST insiders have traded $LFST stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.
Here’s a breakdown of recent trading of $LFST stock by insiders over the last 6 months:
- GP A, LLC TPG sold 20,685,061 shares for an estimated $145,002,277
- ROBERT BESSLER has made 0 purchases and 16 sales selling 295,086 shares for an estimated $2,074,422.
- LISA K MILLER (See Remarks) sold 57,240 shares for an estimated $368,053
- ANN VARANAKIS (Chief People Officer) sold 50,000 shares for an estimated $345,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$LFST Revenue
$LFST had revenues of $403.5M in Q1 2026. This is an increase of 21.17% from the same period in the prior year.
You can track LFST financials on Quiver Quantitative's LFST stock page.
$LFST Hedge Fund Activity
We have seen 121 institutional investors add shares of $LFST stock to their portfolio, and 91 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 13,055,317 shares (-68.1%) from their portfolio in Q4 2025, for an estimated $91,909,431
- FMR LLC added 7,840,028 shares (+20.1%) to their portfolio in Q4 2025, for an estimated $55,193,797
- AUSTRALIANSUPER PTY LTD removed 3,101,010 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $21,831,110
- VANGUARD GROUP INC added 3,086,506 shares (+21.1%) to their portfolio in Q4 2025, for an estimated $21,729,002
- BROWN ADVISORY INC removed 2,997,842 shares (-88.5%) from their portfolio in Q4 2025, for an estimated $21,104,807
- JENNISON ASSOCIATES LLC added 2,843,388 shares (+38.5%) to their portfolio in Q1 2026, for an estimated $18,112,381
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 1,703,725 shares (-79.3%) from their portfolio in Q4 2025, for an estimated $11,994,224
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
$LFST Analyst Ratings
Wall Street analysts have issued reports on $LFST in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BMO Capital issued a "Outperform" rating on 11/13/2025
To track analyst ratings and price targets for $LFST, check out Quiver Quantitative's $LFST forecast page.
$LFST Price Targets
Multiple analysts have issued price targets for $LFST recently. We have seen 6 analysts offer price targets for $LFST in the last 6 months, with a median target of $9.5.
Here are some recent targets:
- Peter Warendorf from Barclays set a target price of $9.0 on 03/06/2026
- Scott Schoenhaus from Keybanc set a target price of $9.0 on 02/26/2026
- Richard Close from Canaccord Genuity set a target price of $10.0 on 02/26/2026
- Kevin Caliendo from UBS set a target price of $12.0 on 02/26/2026
- David Larsen from BTIG set a target price of $11.0 on 02/02/2026
- Sean Dodge from BMO Capital set a target price of $8.0 on 11/13/2025
Full Release
SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health care, today announced that pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”), certain stockholders of the Company (the “Selling Stockholders”) intend to offer 35,000,000 shares of LifeStance’s common stock, par value $0.01 per share (the “Common Stock”). The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.
In addition, the Company has authorized the concurrent purchase from the underwriter of 6,000,000 shares of Common Stock (the “Repurchase”), subject to the completion of the offering. The price per share for the shares to be repurchased by the Company will be the same as the price per share payable by the underwriter to the Selling Stockholders. The underwriter will not receive any underwriting fees for the shares being repurchased by the Company. The Repurchase will be subject to completion of the offering and the satisfaction of other customary conditions. The offering is not conditioned upon the completion of the Repurchase.
J.P. Morgan is acting as the underwriter for the offering.
An automatic shelf registration statement (including a prospectus) relating to the offering of Common Stock was filed by LifeStance with the SEC on May 21, 2024 and became effective upon filing. Before you invest, you should read the prospectus in the shelf registration statement and the documents incorporated by reference therein and the prospectus supplement that the Company has filed with the SEC for more complete information about the Company and the offering. The offering will be made only by means of a prospectus and a related prospectus supplement relating to the offering, copies of which may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected] . A copy of the prospectus and the related prospectus supplement relating to the offering may also be obtained free of charge by visiting EDGAR on the SEC’s website at www.sec.gov .
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Nothing herein should be construed as an offer to sell, or the solicitation of an offer to buy, any shares of Common Stock subject to the Repurchase.
About LifeStance
Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. LifeStance and its supported practices employ over 8,300 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.
Forward-Looking Statements
This press release may contain “forward-looking” statements based on the Company’s beliefs and assumptions and on information currently available to the Company. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions, although not all forward-looking statements contain these identifying words. For example, all statements we make regarding the terms of the proposed public offering and the Repurchase are forward-looking statements.
Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by any forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our growth depends on our ability to recruit, acquire and retain clinicians; we operate in a competitive industry, and if we are not able to compete effectively, our business, results of operations and financial condition would be harmed; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide health care services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; if we are unable to adapt to healthcare reform legislation and other changes in the healthcare industry and in healthcare spending, our business could be harmed; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the SEC.
For the reasons described above, we caution you against relying on any forward-looking statements, which should be read in conjunction with the other cautionary statements included elsewhere in this press release and risk factors discussed from time to time in the Company’s filings with the SEC, which can be found at the SEC’s website at http://www.sec.gov. Any forward-looking statement in this presentation speaks only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise any forward-looking statement after the date of this press release, whether as a result of new information, future developments or otherwise, except as may be required by law. No recipient should, therefore, rely on these forward-looking statements as representing the views of the Company or its management as of any date subsequent to the date of the press release.